Use of Risperidone as Augmentation Treatment for Major Depressive Disorder

Abstract

Spanish

French

Objective

To review the efficacy and safety of risperidone for augmentation treatment In patients with major depressive disorder who fail to achieve adequate response to antidepressant monotherapy.

Data Sources:

A search of MEDLINE (1966-August 2010) and EMBASE (1980-August 2010) was conducted, using the terms risperidone and major depressive disorder. In addition, a manual search of the references cited in each publication identified from the database search was conducted to identify relevant articles.

Study Selection And Data Extraction:

All English-language, peer-reviewed publications identified from the data sources were evaluated. Four clinical trials and 1 subanalysis of a clinical trial were included for analysis.

Data Synthesis:

Risperidone is an atypical antipsychotic that displays antidepressant properties due to its activity at various serotonergic and dopaminergic receptors. Studies have demonstrated that risperidone augmentation may be effective and safe when used at low doses. Although several of the studies identified had limited sample sizes, all studies demonstrated improvement on various standardized depressive symptom assessment scales. Study durations ranged from 4 to 24 weeks, with doses ranging from 0.25 to 2 mg/day. The most common adverse effects associated with risperidone therapy were headache, dry mouth, and increased appetite.

Conclusions:

Clinical evidence suggests that the use of risperidone as adjunctive therapy for treatment-resistant depression may improve rates of response and remission, but long-term effectiveness and safety cannot be determined at this time. Therefore, an adequate trial of first-line agents from different classes and/or a combination of agents from different classes would be recommended prior to initiation of risperidone. If the decision is made to start risperidone, health-care providers should ensure that patients are educated regarding the potential benefits and adverse effects before initiating risperidone.

Keywords

augmentation major depressive disorder risperidone

Get full access to this article

View all access options for this article.

References

Chisholm-Burns

, Wells

, Schwinghammer

. Pharmacotherapy principles & practice. New York, NY: The McGraw-Hill Companies, Inc., 2008: 569–82.

World Health Organization. www.who.int/mental_health/management/depression/definition/en/ (accessed 2010 Apr 19).

Hasin

, Goodwin

, Stinson

, Grant

. Epidemiology of major depressive disorder results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005; 62:1097–106.

Trivedi

, Rush

, Wisniewski

. Evaluation of outcomes with Citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28–40.

Trivedi

, Rush

, Crismon

. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004; 61:669–80.

Papakostas

. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009; 70:16–25.

Richelson

, Souder

. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci 2000; 68:29–39.

Product information. Risperdal (risperidone). Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, June 2009.

Barrett

, Blonde

, Clement

. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596–601.

10.

Lebovitz

. Metabolic consequences of atypical antipsychotic drugs. Psychiatr Q 2003; 74:277–90.

11.

Ray

, Chung

, Murray

. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360:225–35.

12.

Rapaport

, Gharabawi

, Canuso

. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006; 31:2505–13.

13.

Alexopoulos

, Canuso

, Gharabawi

. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry 2008; 16:21–30.

14.

Mahmoud

, Pandina

, Turkoz

. Risperidone for treatment-refractory major depressive disorder. Ann Intern Med 2007; 147:593–602.

15.

Reeves

, Batra

, May

. Efficacy of risperidone augmentation to antidepressants in the management of suicidally in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008; 69:1228–36.

16.

Keitner

, Garlow

, Ryan

. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009; 43:205–14.

17.

Ostroff

, Nelson

. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999; 60:256–9.

18.

Viner

, Chen

, Bakshi

, Kamper

. Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation. J Clin Psychopharmacol 2003; 23:104–6.

19.

American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (2nd edition). Am J Psychiatry 2000: 157(4 suppl):1–45.

20.

Berman

, Marcus

, Swanink

. The efficacy andsafety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68:843–53.

21.

Cutler

, Montgomery

, Feifel

. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009; 70:526–39.

22.

Bauer

, Pretorius

, Constant

. Extended-release quetiapine fumarate as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009; 70:540–9.

23.

American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65:267–72.